Product Details
| Product Name:
Subasumstat |
CAS No.:
1858276-04-6 |
| Purity:
97.05% |
Supply Ability:
10g |
| Release date:
2026/08/08 |
Product Introduction
Bioactivity
| Name | Subasumstat |
| Description | Subasumstat (TAK-981), a selective inhibitor of the SUMOylation enzymatic cascade, has potential immune-activating and antineoplastic activities. |
| In vitro | Methods: HL-60 cells were treated with TAK-981 (10nM; 100nM) for 24 h, and the levels of SUMO-1 and SUMO-2/3 were detected by Western blot. To characterize the effect of the SUMOylation inhibitor TAK-981 on AML cells, we first monitored its effect on SUMOylation in three AML model cell lines HL-60, U937, and THP-1.
Results: TAK-981 significantly reduced the global SUMOylation level mediated by SUMO-1 and SUMO-2/3 at 10 nM concentration and almost completely abolished it at 100 nM concentration. [1] |
| In vivo | Methods: TAK-981 (15 mg/kg) was injected intravenously into the tumor model mice to detect the anti-tumor activity in vivo.
Results: TAK981 significantly inhibited tumor growth. [2] |
| Storage | The compound is unstable in solution. Please use soon,
Powder: -20°C for 3 years
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3.46 mM), Sonication is recommended.
DMSO : 122.5 mg/mL (211.9 mM), Sonication is recommended.
|
| Keywords | Ubiquitin ligase | Ubiquitin conjugating enzyme | Ubiquitin activating enzyme | TAK981 | TAK 981 | SUMOylation | Subasumstat | Inhibitor | inhibit | E3Enzyme | E3 ligating enzyme | E3 Enzyme | E2Enzyme | E2 Enzyme | E2 conjugating enzyme | E1Enzyme | E1/E2/E3 Enzyme | E1 Enzyme | E1 activating enzyme |
| Inhibitors Related | T521 | NAcM-OPT | Nutlin-3 | Yucasin | BC-1293 | EN219 | NSC232003 | Auxinole | Indole-3-carbinol | Idasanutlin | TRIM25 ligand-1 | Direct Black 38 |
| Related Compound Libraries | Bioactive Compounds Library Max | Failed Clinical Trials Compound Library | ReFRAME Related Library | HIF-1 Signaling Pathway Compound Library | Post-Translational Modification Compound Library | NO PAINS Compound Library | Immunology/Inflammation Compound Library | Preclinical Compound Library | Bioactive Compound Library Plus |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States